BFEC
GLMD icon

Benjamin F. Edwards & Company’s Galmed Pharmaceuticals GLMD Stock Holding History

Benjamin F. Edwards & Company’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed – – 1836
2022
Q4 		$0 Buy
+1
New +$65 ﹤0.01% 1861

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Benjamin F. Edwards & Company's GLMD Position: Q1 2023 in Review

Benjamin F. Edwards & Company sold out of Galmed Pharmaceuticals (GLMD) in Q1 2023, closing a stake of 1 share.

Benjamin F. Edwards & Company first reported a position in GLMD in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 20 funds tracked by Wall St. Rank hold GLMD as of Q1 2023.

  • Benjamin F. Edwards & Company reported no remaining Galmed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 1 Galmed Pharmaceuticals share in Q1 2023.
  • Benjamin F. Edwards & Company first reported a position in Galmed Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Galmed Pharmaceuticals position peaked at $0 in Q4 2022.
  • 20 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2023, filed 27 Apr 2023.